$GLUE 8-K SEC Filings

Filed On	Filing
01 Oct 2026	8-K: Regulation FD Disclosure; Other Events Degrading Proteins, Making Medicines MRT-8102 GFORCE-1 Clinical Study Results October 1, 2026 Exhibit 99.2
08 Sep 2026	8-K: Regulation FD Disclosure; Other Events Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
06 Aug 2026	8-K: Results of Operations and Financial Condition
11 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
07 May 2026	8-K: Results of Operations and Financial Condition
17 Mar 2026	8-K: Results of Operations and Financial Condition
10 Feb 2026	8-K: Departure/Election of Directors or Officers; Compensation
09 Jan 2026	8-K: Entry into a Material Definitive Agreement; Other Events
07 Jan 2026	8-K: Other Events
07 Jan 2026	8-K: Regulation FD Disclosure; Other Events
16 Dec 2025	8-K: Regulation FD Disclosure; Other Events
06 Nov 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
15 Sep 2025	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
07 Aug 2025	8-K: Results of Operations and Financial Condition
13 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
08 May 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
20 Mar 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
10 Jan 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
13 Dec 2024	8-K: Departure/Election of Directors or Officers; Compensation
05 Dec 2024	8-K: Regulation FD Disclosure; Other Events

Comments